Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Castle Biosciences Inc

CSTL
Current price
19.83 USD -0.12 USD (-0.60%)
Last closed 19.95 USD
Sector Healthcare
Industry Diagnostics & Research
Exchange NASDAQ
Capitalization 537 402 688 USD
Yield for 12 month -16.72 %
Week
Month
Year
CSTL
21.11.2021 - 28.11.2021

Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary 35-GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was incorporated in 2007 and is headquartered in Friendswood, Texas. Address: 505 South Friendswood Drive, Friendswood, TX, United States, 77546

Analytics

WallStreet Target Price

33 USD

P/E ratio

Dividend Yield

Current Year

+137 039 000 USD

Last Year

+94 085 000 USD

Current Quarter

+61 493 000 USD

Last Quarter

+50 138 000 USD

Current Year

+105 030 000 USD

Last Year

+78 263 000 USD

Current Quarter

+50 174 000 USD

Last Quarter

+39 080 000 USD

Key Figures CSTL

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -73 504 000 USD
Operating Margin TTM -15.68 %
PE Ratio
Return On Assets TTM -11.95 %
PEG Ratio
Return On Equity TTM -18.94 %
Wall Street Target Price 33 USD
Revenue TTM 192 006 000 USD
Book Value 14.35 USD
Revenue Per Share TTM 7.21 USD
Dividend Share
Quarterly Revenue Growth YOY 66.1 %
Dividend Yield
Gross Profit TTM 105 030 000 USD
Earnings Share -2.84 USD
Diluted Eps TTM -2.84 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY -92.6 %
Profit Margin -39.32 %

Dividend Analytics CSTL

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History CSTL

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation CSTL

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 1.678
Price Sales TTM 2.7989
Enterprise Value EBITDA -5.0796
Price Book MRQ 1.393

Financials CSTL

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators CSTL

For 52 weeks

9.26 USD 29.59 USD
50 Day MA 16.32 USD
Shares Short Prior Month 1 427 654
200 Day MA 18.91 USD
Short Ratio 3.98
Shares Short 1 304 246
Short Percent 5.79 %